Insufficient scRNA-seq data for expression of UBD at single-cell level.
Insufficient scRNA-seq data for expression of UBD at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
kidney | 100% | 73.21 | 89 / 89 | 1% | 0.01 | 9 / 901 |
spleen | 99% | 56.68 | 239 / 241 | 0% | 0 | 0 / 0 |
liver | 85% | 48.37 | 191 / 226 | 10% | 0.17 | 41 / 406 |
pancreas | 91% | 76.76 | 299 / 328 | 1% | 0.02 | 2 / 178 |
lung | 79% | 25.00 | 454 / 578 | 2% | 0.03 | 19 / 1155 |
intestine | 61% | 35.10 | 585 / 966 | 16% | 0.60 | 84 / 527 |
prostate | 75% | 39.03 | 184 / 245 | 0% | 0 | 0 / 502 |
breast | 63% | 15.40 | 289 / 459 | 1% | 0.02 | 15 / 1118 |
stomach | 47% | 18.66 | 169 / 359 | 13% | 0.34 | 38 / 286 |
bladder | 48% | 5.86 | 10 / 21 | 7% | 0.21 | 36 / 504 |
esophagus | 53% | 13.73 | 773 / 1445 | 1% | 0.02 | 2 / 183 |
adipose | 54% | 12.24 | 647 / 1204 | 0% | 0 | 0 / 0 |
thymus | 33% | 11.54 | 216 / 653 | 0% | 0.00 | 1 / 605 |
skin | 26% | 3.13 | 465 / 1809 | 4% | 0.06 | 17 / 472 |
blood vessel | 20% | 2.43 | 271 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 20% | 24.65 | 185 / 929 | 0% | 0 | 0 / 0 |
uterus | 15% | 2.43 | 25 / 170 | 2% | 0.02 | 8 / 459 |
adrenal gland | 9% | 0.99 | 22 / 258 | 0% | 0 | 0 / 230 |
ovary | 5% | 0.56 | 9 / 180 | 1% | 0.02 | 4 / 430 |
heart | 6% | 0.61 | 51 / 861 | 0% | 0 | 0 / 0 |
muscle | 5% | 0.39 | 39 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 3% | 0.04 | 1 / 29 |
brain | 3% | 0.58 | 72 / 2642 | 0% | 0 | 0 / 705 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0034612 | Biological process | response to tumor necrosis factor |
GO_0034341 | Biological process | response to type II interferon |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0006508 | Biological process | proteolysis |
GO_0043011 | Biological process | myeloid dendritic cell differentiation |
GO_0070842 | Biological process | aggresome assembly |
GO_0032446 | Biological process | protein modification by small protein conjugation |
GO_1901990 | Biological process | regulation of mitotic cell cycle phase transition |
GO_0043065 | Biological process | positive regulation of apoptotic process |
GO_0005654 | Cellular component | nucleoplasm |
GO_0001650 | Cellular component | fibrillar center |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0016235 | Cellular component | aggresome |
GO_0005634 | Cellular component | nucleus |
GO_0070628 | Molecular function | proteasome binding |
GO_0005515 | Molecular function | protein binding |
Gene name | UBD |
Protein name | Ubiquitin D (Diubiquitin) (Ubiquitin-like protein FAT10) UBD (Ubiquitin D) |
Synonyms | FAT10 |
Description | FUNCTION: Ubiquitin-like protein modifier which can be covalently attached to target protein and subsequently leads to their degradation by the 26S proteasome, in a NUB1-dependent manner. Probably functions as a survival factor. Conjugation ability activated by UBA6. Promotes the expression of the proteasome subunit beta type-9 (PSMB9/LMP2). Regulates TNF-alpha-induced and LPS-mediated activation of the central mediator of innate immunity NF-kappa-B by promoting TNF-alpha-mediated proteasomal degradation of ubiquitinated-I-kappa-B-alpha. Required for TNF-alpha-induced p65 nuclear translocation in renal tubular epithelial cells (RTECs). May be involved in dendritic cell (DC) maturation, the process by which immature dendritic cells differentiate into fully competent antigen-presenting cells that initiate T-cell responses. Mediates mitotic non-disjunction and chromosome instability, in long-term in vitro culture and cancers, by abbreviating mitotic phase and impairing the kinetochore localization of MAD2L1 during the prometaphase stage of the cell cycle. May be involved in the formation of aggresomes when proteasome is saturated or impaired. Mediates apoptosis in a caspase-dependent manner, especially in renal epithelium and tubular cells during renal diseases such as polycystic kidney disease and Human immunodeficiency virus (HIV)-associated nephropathy (HIVAN). . |
Accessions | ENST00000383641.2 O15205 ENST00000429935.2 ENST00000421519.2 ENST00000377050.5 A0A0G2JH67 ENST00000414436.2 ENST00000383547.3 ENST00000432676.2 |